All peptides
GLP-1Research peptide
Retatrutide
Retatrutide is an investigational triple agonist peptide targeting GLP-1, GIP, and glucagon receptors. It is being studied in Phase 3 trials by Eli Lilly for metabolic research endpoints including body weight and glycemic parameters.
Also known as: LY3437943, Triple G
Technical information
Molecular weight
4731.3 g/mol
Half-life
~6 days (subcutaneous)
Sequence
Modified 39-amino acid peptide (GLP-1/GIP/glucagon triple agonist)
Common research doses
1-12 mg weekly (research protocols)
Research areas
Metabolic researchWeight studiesGlycemic controlTriple agonism
For research purposes only. PepAssure provides vendor information as a verification service and does not endorse or recommend any specific use. Consult qualified research protocols and institutional review boards.
Best Verified Vendors for Retatrutide
Ranked by PVS score — independent verification, no paid placements.